We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$3B
1-Year Est. Return
46.72%
This Fund
S&P 500
This Quarter
Est. Return
+3.75%
1 Year Est. Return
+46.72%
3 Year Est. Return
+56.07%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3B
AUM Growth
-$129M
(-4.1%)
Cap. Flow
-$405M
Cap. Flow
% of AUM
-13.51%
Top 10 Holdings %
Top 10 Hldgs %
30.38%
Holding
104
New
28
Increased
19
Reduced
31
Closed
14
Top Buys
| 1 |
iRhythm Holdings
IRTC
|
+$56.7M |
| 2 |
Guardant Health
GH
|
+$50.2M |
| 3 |
GENB
Generate Biomedicines
GENB
|
+$43.9M |
| 4 |
Monte Rosa Therapeutics
GLUE
|
+$43.2M |
| 5 |
argenx
ARGX
|
+$42.2M |
Top Sells
| 1 |
Edgewise Therapeutics
EWTX
|
+$82.6M |
| 2 |
Align Technology
ALGN
|
+$59.5M |
| 3 |
CG Oncology
CGON
|
+$50.2M |
| 4 |
RAPT
RAPT Therapeutics
RAPT
|
+$31.5M |
| 5 |
Legend Biotech
LEGN
|
+$28.2M |
Sector Composition
| 1 | Healthcare | 87.27% |
| 2 | Financials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BIOA
51
BioAge Labs
BIOA
$1.01B
| $21M | 0.7% |
+1,200,587
| New | +$23.1M |
|
52
CVS Health
CVS
$135B
| $20.9M | 0.7% |
290,700
-273,500
| -48% | -$21.1M |
|
53
Tarsus Pharmaceuticals
TARS
$2.51B
| $18.6M | 0.62% |
+265,715
| New | +$18.6M |
|
54
Elevance Health
ELV
$84.8B
| $18.2M | 0.61% |
+62,080
| New | +$20.4M |
|
55
OrthoPediatrics
KIDS
$507M
| $17.5M | 0.58% |
1,100,370
| – | – |
|
56
enGene Therapeutics
ENGN
$127M
| $16.7M | 0.56% |
2,456,870
-674,449
| -22% | -$6M |
|
57
Nektar Therapeutics
NKTR
$2.31B
| $16M | 0.53% |
+222,701
| New | +$12.7M |
|
58
Acadia Healthcare
ACHC
$2.97B
| $15.1M | 0.5% |
+645,900
| New | +$11.7M |
|
59
Oric Pharmaceuticals
ORIC
$1.15B
| $14.3M | 0.48% |
+1,128,040
| New | +$12.8M |
|
60
Aveanna Healthcare
AVAH
$2.09B
| $14.2M | 0.47% |
+2,203,506
| New | +$17M |
|
61
X4 Pharmaceuticals
XFOR
$368M
| $13.5M | 0.45% |
3,272,954
-95,950
| -3% | -$359K |
|
62
Kiniksa Pharmaceuticals
KNSA
$4.75B
| $13.1M | 0.44% |
272,522
-41,301
| -13% | -$1.83M |
|
63
Evolus
EOLS
$392M
| $12.8M | 0.43% |
3,105,209
| – | – |
|
64
TG Therapeutics
TGTX
$8.64B
| $11.9M | 0.4% |
+358,800
| New | +$10.7M |
|
65
Surrozen
SRZN
$253M
| $11.5M | 0.38% |
396,100
-73,900
| -16% | -$1.77M |
|
66
Centene
CNC
$32.9B
| $10.8M | 0.36% |
+330,000
| New | +$13.5M |
|
|
CLYM
67
Climb Bio
CLYM
$794M
| $10.5M | 0.35% |
+1,529,675
| New | +$8.82M |
|
68
Compass Therapeutics
CMPX
$385M
| $10.4M | 0.35% |
1,965,106
-821,672
| -29% | -$4.74M |
|
69
Ionis Pharmaceuticals
IONS
$9.04B
| $9.83M | 0.33% |
+130,862
| New | +$10.3M |
|
|
HLXC
70
Helix Acquisition Corp III
HLXC
$231M
| $9.27M | 0.31% |
+900,000
| New | +$9.21M |
|
71
Vor Biopharma
VOR
$980M
| $8.33M | 0.28% |
+466,774
| New | +$6.58M |
|
72
Revolution Medicines
RVMD
$39.2B
| $8.26M | 0.28% |
+84,900
| New | +$8.57M |
|
|
GRAL
73
GRAIL Inc
GRAL
$3.19B
| $7.38M | 0.25% |
142,755
| – | – |
|
74
Aclaris Therapeutics
ACRS
$782M
| $6.37M | 0.21% |
+1,699,116
| New | +$5.73M |
|
75
Denali Therapeutics
DNLI
$3.65B
| $5.69M | 0.19% |
+296,324
| New | +$5.9M |
|
Similar funds
NC
VVP
SP
DIG
ECP
PCM
ROTUOC
SM